Long-term efficacy and safety of antitumour necrosis factor alpha treatment in rhupus: an open-label study of 15 patients.
Fiche publication
Date publication
janvier 2017
Journal
RMD open
Auteurs
Membres identifiés du Cancéropôle Est :
Pr GOTTENBERG Jacques-Eric, Pr MARTIN Thierry
Tous les auteurs :
Danion F, Sparsa L, Arnaud L, Alsaleh G, Lefebvre F, Gies V, Martin T, Lukas C, Durckel J, Ardizzone M, Javier RM, Kleinmann JF, Moreau P, Blaison G, Goetz J, Chatelus E, Gottenberg JE, Sibilia J, Sordet C
Lien Pubmed
Résumé
The efficacy of antitumour necrosis factor alpha (anti-TNF-α) treatment is well recognised in rheumatoid arthritis (RA) but remains controversial in systemic lupus erythematosus (SLE). Therefore, the role of anti-TNF-α treatment in 'Rhupus', a disease sharing features of RA and SLE, is still debated.
Référence
RMD Open. 2017 ;3(2):e000555